Table 1.
Overview of clinical efficacy of combination treatments with Crizotinib and EGFR-TKIs for acquired MET amplification in EGFRm+ NSCLC patients. * Only genomic or phenotypical alterations considered as potential mechanisms of TKI resistance are indicated.
|
The Preceding Treatment |
Detection Methods |
Number of Patients |
Treatment for Acquired MET Amplification |
PFS Months |
Multiple Genomic/ Phenotypical Co-Alterations in Rebiopsy (Yes/No) * |
References | |
|---|---|---|---|---|---|---|---|
| 1 | Osimertinib (9 months) | NGS, IHC, and FISH (all cases) | 1 (case 1) | Crizotinib + Osimertinib | 9 | Yes | current article |
| Osimertinib (6 months) | 1 (case 2) | Crizotinib + Osimertinib | 6 | Yes | |||
| Osimertinib + Alectinib (9 months) | 1 (case 3) | Crizotinib + Osimertinib | 9 | Yes | |||
| Atezolizumab (4 months) | 1 (case 4) | Crizotinib + Gefitinib | 18 | No | |||
| Osimertinib (26 months) | 1 (case 5) | Crizotinib + Osimertinib | 11 | Yes | |||
| 2 | 1st gen. EGFR-TKI | FISH | 14 | Crizotinib (8) | 6.0 | No | [46] |
| Crizotinib + EGFR-TKI (6) | 12.6 | ||||||
| 3 | 1st/2nd gen. EGFR-TKI as first line (8) chemotherapy (6) as second line | NGS FISH | 8 |
Crizotinib (2) Crizotinib + EGFR-TKI (6) |
1.4 | Yes | [31] |
| 4 | 3rd gen EGFR-TKI | FISH | 1 | Crizotinib alone | 1.5 | Yes | [47] |
| 5 | 1st gen. EGFR-TKI (40) 2nd gen. EGFR-TKI (3) 3rd gen. EGFR-TKI (26) 1st gen. EGFR-TKI after 2. line chemotherapy (1) |
NGS FISH | 67 |
Crizotinib (10) Crizotinib + EGFR-TKI (35) Chemotherapy (22) |
2.3 5.0 2.9 | Yes | [48] |
| 6 | 1st gen. EGFR-TKI (4) 2nd gen. EGFR-TKI (7) |
NGS | 11 | 1st/2nd gen. EGFR-TKI + Crizotinib (6) 3rd gen. EGFR-TKI + Crizotinib (5) |
5.8 | Yes | [49] |
| 7 | 1st gen. EGFR-TKI Pemetrexed 3rd gen. EGFR-TKI |
NGS FISH | 1 | Crizotinib + Osimertinib | 19 | No | [14] |
| 8 | Osimertinib rechallenge | NGS FISH | 1 | Crizotinib + Osimertinib | 6 | No | [15] |
| 9 | Chemotherapy | NGS FISH | 1 | Crizotinib + Erlotinib | 4 | Yes | [16] |
| 10 | Erlotinib Local ablative therapy | NGS FISH | 1 | Crizotinib + Osimertinib + local ablative therapy | 9 | Yes | [17] |
| 11 | Chemotherapy | cfDNA | 1 | Crizotinib + Osimertinib | 4 | Yes | [18] |
| 12 | Gefitinib | cfDNA | 1 | Crizotinib + Osimertinib | 3 | Yes | [19] |
| 13 | Erlotinib | cfDNA | 1 | Crizotinib + Erlotinib | 2 | Yes | [55] |
| 14 | EGFR-TKIs | NGS, IHC and FISH | 1 | Crizotinib + Osimertinib | 11 | Yes | [22] |
| 15 | Afatinib | NGS | 1 | Crizotinib + Afatinib | 4 | Yes | [56] |